Doxycycline In Lymphangioleiomyomatosis (LAM)

Learn more about:
Related Clinical Trial
Doxycycline In Lymphangioleiomyomatosis (LAM) Effect of Fasting on the Size of Abdominal Lymphatic Tumors in Women Turmeric as Treatment in Epilepsy Study of the Disease Process of Lymphangioleiomyomatosis RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM The Effectiveness and Safety of Vagus Nerve Stimulation for TRE The Effectiveness and Safety of Resective Epilepsy Surgery for TRE Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B) Safety of Simvastatin in LAM and TSC Studies of Autistic Patients: Gene Networks and Clinical Subtypes Topical Rapamycin to Erase Angiofibromas in TSC Rapalogues for Autism Phenotype in TSC: A Feasibility Study A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD Everolimus for Cancer With TSC1 or TSC2 Mutation Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex The Cognitive Variability in NF1 and TSC Monozygotic Twins Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC) Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1) Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy – Tuberous Sclerosis Complex A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6) Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC) Clinical Presentation and Renal Outcome of Patients With Tuberous Sclerosis Complex and/or Renal Angiomyolipoma in the Great West Region of France Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex Characterization of Patients With Tuberous Sclerosis Complex, Lymphangioleiomyomatosis and Angiomyolipoma Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC) Everolimus (RAD001) Therapy of Giant Cell Astrocytoma in Patients With Tuberous Sclerosis Complex JASPER Early Intervention for Tuberous Sclerosis Studies in Patients With Tuberous Sclerosis Complex Treatment of Renal Angiomyolipomas in Tuberous Sclerosis by Beta-blockers Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1) Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM) Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship Genetic Heterogeneity and Genotype-phenotype Correlation of Children and Adults With Tuberous Sclerosis Complex (TuScCom) Early Biomarkers of Autism in Infants With Tuberous Sclerosis Complex (TSC) Tuberous Sclerosis Complex Natural History Study: Renal Manifestations Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC) Study of Skin Tumors in Tuberous Sclerosis

Brief Title

Doxycycline In Lymphangioleiomyomatosis (LAM)

Official Title

A Randomised, Double Blind, Placebo Controlled Trial of Doxycycline in Lymphangioleiomyomatosis.

Brief Summary

      The purpose of the study is to test if the drug doxycycline is effective in slowing the
      progression of lung disease in LAM. Lymphangioleiomyomatosis (LAM) is a rare lung disease
      which affects young women. Women with LAM develop enlarged air spaces in the lungs called
      cysts, caused by an excess of matrix metalloproteinases (MMPs), protein-digesting enzymes.
      LAM is associated with kidney tumours, called angiomyolipomas, and causes recurrent lung
      collapse, breathlessness and death or need for lung transplant. There is no proven treatment.
      Doxycycline, a commonly used antibiotic can block MMP production and a small number of
      patients have shown some benefit from doxycycline. The investigators will perform a study to
      test if doxycycline can slow the fall in lung function in patients with LAM. Forty patients
      who consent to participate will take doxycycline or a placebo (dummy) tablet for two years in
      addition to their standard treatment.
    

Detailed Description

      Summary

      We will perform a 2 year double blind, placebo controlled trial of doxycycline in 40 patients
      with LAM. The main endpoints will be change in FEV1, other measures of efficacy, safety and
      dose required to suppress MMP activity. After clinical evaluation, lung function, shuttle
      walk, QoL assessment, blood tests, serum and urine MMPs (termed full assessment) plus
      baseline chest X-ray patients will be randomised to doxycycline 50 mg od or placebo. Patients
      will be assessed at 2 weeks for a safety screen, every 3 months for clinical evaluation and
      spirometry and at 12 and 24 months for full assessment. At 3 months urine zymography will be
      performed to see if MMPs are present in urine at the prescribed dose. Doxycycline will be
      increased to 100 mg bd at three months after urine zymography has been performed. To avoid
      withholding treatment from those who decline rapidly, patients who, on two occasions, have
      either a fall from baseline FEV1 of 300 ml or fall in resting SaO2 of 3% will be assessed by
      an independent expert (AET). Patients receiving placebo will be given the option of
      doxycycline according to protocol. Those receiving doxycycline the option of continuing in
      the study or withdrawal. These patients and those withdrawn due to recurrent pneumothorax,
      increase in chylous effusion or bleeding angiomyolipoma will be included in a composite
      safety endpoint and analysed on an intention to treat basis. Power calculations based on
      retrospective cohorts(Johnson and Tattersfield 1999) show that 20 patients per group will
      give 80% power to detect a 70 ml/year difference in FEV1 based an assumed SD for a fall in
      FEV1 of 75 ml/year. The mean slope of regression lines for FEV1 and FVC, plus change DLCO,
      shuttle walk distance and QoL in the doxycycline and placebo groups will be compared by
      parametric or non-parametric analysis dependent on data, time to composite safety endpoint by
      Caplan-Meier analysis, complications and adverse events by Chi Square test.

      1. Introduction

      Lymphangioleiomyomatosis Lymphangioleiomyomatosis (LAM) is a disease of the lungs and
      lymphatics, which can occur sporadically or in association with tuberous sclerosis complex
      (TSC). The disease is rare, occurring in 1-2 / million of the population but in up to 40% of
      women with TSC LAM almost exclusively affects women, generally developing before the
      menopause. The disease is characterised by progressive pulmonary cystic change, recurrent
      pneumothorax, chylous pleural collections and, in most cases, progressive respiratory
      failure. Abdominal manifestations caused by obstruction and dilation of the axial lymphatics
      include lymphadenopathy, cystic lymphatic masses (lymphangioleiomyomas), chylous ascites and
      angiomyolipoma (a benign tumour). Survival in LAM is, 70 90% at 10 yrs, although this is
      highly variable since long-term survivors have been described. Diagnosis is made by a
      combination of clinical features and computed tomography scanning or, in cases of doubt, lung
      biopsy. In patients with rapidly progressive disease, hormone treatment (predominantly
      progesterone) has been used, although no firm evidence supports its use. Otherwise, treatment
      is aimed at complications including pneumothorax, chylous collections and extra-pulmonary
      manifestations. The only treatment for severe LAM is currently lung transplantation(Johnson
      2006). Recently identification of abnormalities in the tuberous sclerosis complex (TSC) genes
      in sporadic and TSC associated LAM have identified dysregulation of the mTOR pathway in LAM
      (Carsillo, Astrinidis et al. 2000; Sato, Seyama et al. 2002) and have lead to clinical trials
      of mTOR inhibitors such as rapamycin in LAM and TSC. At the time of writing these have not
      been reported but appear promising.

      Background and preliminary data Cystic lung destruction is the hallmark of pulmonary LAM and
      generally results in respiratory failure over a variable period of time(Johnson 2006).
      Over-activity of proteases including elastase, trypsin and the matrix metalloproteinases
      (MMPs) is responsible for parenchymal destruction in emphysema and other lung diseases. The
      MMPs are a family of zinc dependent proteolytic enzymes with proteolytic activities against
      extra-cellular matrix proteins. The MMPs are overexpressed in inflammatory and neoplastic
      diseases where in addition to processing extra-cellular matrix they also have roles in
      metastasis, angiogenesis, growth factor activation and inactivation(Stamenkovic 2003). MMPs
      -1, -2, and -9 are involved in the sequential digestion of collagen and gelatin and are
      strongly expressed in the walls of cysts where it is thought they contribute to parenchymal
      destruction in LAM(Matsui, Takeda et al. 2000). Further, MMPs can be detected by gelatin
      zymography in the urine of patients with LAM but not controls. Doxycycline is a tetracycline
      antibiotic in common clinical use. In addition to its antimicrobial action it inhibits the
      synthesis and activity of several MMPs and inhibits proliferation of a range of cell types
      including arterial smooth muscle, cancer cells and cancer model systems(Bendeck, Conte et al.
      2002; Duivenvoorden, Popovic et al. 2002; Onoda, Ono et al. 2004). In preliminary experiments
      we have demonstrated that primary LAM derived and angiomyolipoma cells produce MMP-2 and -7
      and that MMP expression and proliferation in these cells in inhibited by doxycycline.

      Preliminary clinical data of doxycycline in LAM In a preliminary open label study of
      doxycycline (50 - 100 mg qds) in 10 patients with LAM, doxycycline improved 6 minute walk
      distance) and Borg dyspnoea score (Glassberg et al. Data presented at the LAM Foundation
      International Research Conference, Cincinnati Ohio 2006). In a single case report, Moses et
      al. observed an improvement in FEV1 and oxygenation during exercise in a patient with LAM
      treated with 100mg doxycycline daily (Moses, Harper et al. 2006). In both of these cases
      MMP-2 and -9 were initially present in the patient's urine and was undetectable after
      treatment with doxycycline. In a study of 14 patients, doxycycline 100mg bd is known to give
      a mean plasma concentration of 4.41 µg/ml (range 1.9-9.4 µg/ml)(Prall, Longo et al. 2002).

      Specific issues in orphan disease clinical trials and rationale for trial design Studying
      orphan diseases presents specific challenges, specifically the limited number of patients
      available, wide geographic distribution and low priority for funding due to the perceived
      poor economic benefit. Patients are well informed about potential developments due to patient
      groups and internet based information(Tattersfield and Glassberg 2006) and may obtain
      potential treatments 'off label' making definitive research studies impossible. As LAM is
      rare, cohorts drawn from a wide area are required for studies to achieve adequate power. We
      have 15 years experience of LAM research and from our UK LAM database estimate there are
      approximately 120 patients in the UK. We are currently performing an open label study of
      Sirolimus in LAM and tuberous sclerosis (TESSTAL, a Study of The Efficacy and Safety of
      Sirolimus (Rapamycin) Therapy for Renal Angiomyolipomas in Patients with Tuberous Sclerosis
      Complex And Sporadic Lymhangioleiomyomatosis). This included six patients with LAM whom we
      found to be well motivated and will travel long distances for study visits (including
      Cornwall, Kent and Perth). Despite the known adverse effects of rapamycin six of eight
      eligible (i.e. with LAM and angiomyolipoma) patients invited took part in the study. The
      current study protocol has been designed as a simple protocol which is both inclusive of most
      patients with LAM and has a follow up which is similar to routine clinical care which we hope
      will facilitate recruitment. In addition the protocol is less demanding than that of the
      TESSTAL study. As most patients are known to us via our database or clinical contacts we
      expect recruitment to be complete within six months.

      Designing a definitive study is difficult without having an estimate of the likely size of
      effect, if this is large, as suggested by the one case report(Moses, Harper et al. 2006) a
      small number of patients are needed. If it is small as seems more likely a priori, a larger
      number of patients are needed requiring European collaboration and considerably greater
      funding. We therefore designed a pragmatic pilot study using a single geographic population
      with a simple, inexpensive protocol which will serve several functions, specifically to: (1)
      determine the optimum dose of doxycycline needed to suppress MMP production. (2) define the
      safety profile of doxycycline in LAM. (3) provide evidence of efficacy and size of effect.
      (4) provide data to help optimise the design and logistics of future trials.

      2 Study aims/objectives

      Hypothesis Doxycycline will prevent matrix metalloproteinase dependent tissue destruction in
      lymphangioleiomyomatosis (LAM) thus preserving lung function, exercise capacity and quality
      of life.

      We will perform a randomised placebo controlled trial of doxycycline on rate of decline of
      FEV1 over two years against matched placebo. This study will:

        1. determine the optimum dose of doxycycline needed to suppress MMP production.

        2. define the safety profile of doxycycline in LAM.

        3. provide evidence for efficacy and size of effect.

        4. provide data to help optimise the design and logistics of future trials.

      With the data obtained we will be in a strong position to apply for European funding for a
      European wide trial should this still be required.

      3 Investigational plan

      Patient population and recruitment

      Forty patients with either sporadic LAM or TSC-LAM will be recruited from the UK LAM
      database, physician referrals, LAM Action (a patients group for women with LAM) and the
      Tuberous Sclerosis Association. Patients will be contacted by mail by the principal
      investigator. Potential participants will receive a preliminary information sheet and
      response sheet for return by prepaid post. Those that express a potential interest in
      participating will be offered a face to face interview with one of the study doctors to
      assess eligibility, answer questions, obtain details of all physicians involved in their care
      and obtain written consent prior to enrolment. We anticipate recruitment will be complete
      within 12 months of starting the study.
    

Study Phase

Phase 4

Study Type

Interventional


Primary Outcome

Mean rate of change of FEV1 over 24 months on doxycycline compared with placebo.

Secondary Outcome

 Rate change FVC over 24 months Change DLCO at 12 & 24 mths Change in shuttle walk distance at 12 & 24 mths Change in QOL at 12 & 24 mths Time to composite safety endpoint Number complications Number respiratory infections Adverse effects

Condition

Lymphangioleiomyomatosis

Intervention

Doxycycline

Study Arms / Comparison Groups

 Doxycycline
Description:  

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Drug

Estimated Enrollment

24

Start Date

July 2009

Completion Date

January 2013

Primary Completion Date

January 2013

Eligibility Criteria

        Inclusion Criteria:

          -  Sporadic LAM diagnosed either by cystic lung disease on HRCT classical of LAM plus
             angiomyolipoma or chylous effusion or cystic lung disease on HRCT and tissue biopsy
             showing LAM or angiomyolipoma

          -  TSC-LAM diagnosed by cystic lung disease on HRCT and tuberous sclerosis diagnosed by
             TSC consensus criteria(13).

          -  Patients with either an FEV1 below 80% predicted or evidence of a 20% deterioration in
             FEV1.

          -  Hormone and bronchodilator treatment for LAM* is allowed providing treatment has not
             changed in the three months prior to enrollment.

               -  progesterone, GnRh agonists and bronchodilators

        Exclusion Criteria:

          -  Inability to give informed consent.

          -  Mental retardation.

          -  Age less than 18 years.

          -  Pneumothorax, chylous effusion, bleeding angiomyolipoma or change in hormone treatment
             within 3 months.

          -  Previous organ transplantation.

          -  Severe or uncontrolled epilepsy.

          -  Use of any oral contraceptive pill.

          -  Pregnancy or breast feeding. Pre-menopausal patients must be willing to use
             appropriate birth control measures to avoid pregnancy while enrolled in the study.

          -  Major systemic diseases (malignancy, myocardial infarction or unstable angina, type1
             diabetes, severe hypertension, liver cirrhosis).

          -  Use of drugs known to interact with doxycycline, including anticoagulation with
             warfarin.

          -  Anticoagulation with warfarin.

          -  Hypersensitivity to tetracyclines.

          -  Treatment with mTOR inhibitor within the previous 3 months (sirolimus, everolimus).

          -  Use of doxycycline or other experimental drug within the previous three months.
      

Gender

Female

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Simon R Johnson, DM FRCP, , 

Location Countries

United Kingdom

Location Countries

United Kingdom

Administrative Informations


NCT ID

NCT00989742

Organization ID

07061


Responsible Party

Sponsor

Study Sponsor

University of Nottingham


Study Sponsor

Simon R Johnson, DM FRCP, Principal Investigator, University of Nottingham


Verification Date

December 2015